Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System

NCT05165602 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05165602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05165602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
Lead sponsor
Peking University
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
May 1, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive gastric cancer